Beam Therapeutics Inc. (NASDAQ: BEAM) is evaluating its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease, an inherited blood disorder. BEAM's pipeline of gene editing therapies is based on its proprietary base editing technology. The company is advancing its base editing technology across three disease area portfolios, namely, hematology, immunology/oncology and genetic diseases. Here are some reasons why investors should consider betting on Beam Therapeutics stock. Good Rank and Rising Estimates: Beam Therapeutics currently has a Zacks Rank #2 (Buy). In the past 90 days, the estimate for Beam Therapeutics' 2024 loss per share has narrowed from $5.53 to $4.68. During the same period, loss per share estimate for 2025 has narrowed from $5.04 to $4.66. Hematology Program Picking Up Pace: The company is pursuing an ex vivo, autologous transplant-based approach for SCD and beta-thalassemia. It is currently developing BEAM-101 in the phase I/II BEACON study for SCD. Dosing and engraftment for the three patients in the sentinel cohort of the BEACON study have been completed. Data from multiple patients in the study is expected in the second half of 2024. BEAM is also advancing its engineered stem cell antibody paired evasion conditioning strategy to face the toxicity challenges of autologous transplant in SCD and beta-thalassemia patients. Both SCD and beta-thalassemia have a ...